$ABUS
Arbutus Biopharma Corp Stock $abus

$abus Overview Financials Valuation SEC Filings Company Website

2019 Q1 Form 10-K Financial Statement

#000144702819000006 Filed on March 07, 2019

Income Statement

Concept	2019 Q1	2018 Q4	2018 Q3
Revenue	$679.0K	$1.678M	$1.587M
YoY Change	-52.72%	-33.78%	-76.97%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$4.410M	$5.930M	$2.630M
YoY Change	20.16%	67.51%	-28.14%
% of Gross Profit
Research & Development	$14.71M	$11.06M	$16.57M
YoY Change	5.47%	-37.93%	6.62%
% of Gross Profit
Depreciation & Amortization	$509.0K	$500.0K	$497.0K
YoY Change	-15.45%	-19.35%	-16.19%
% of Gross Profit
Operating Expenses	$19.88M	$17.50M	$34.01M
YoY Change	0.17%	-20.42%	71.88%
Operating Profit	-$19.20M	-$16.90M	-$32.43M
YoY Change	4.3%	-71.94%	151.42%
Interest Expense	$12.00K	-$2.380M	$0.00
YoY Change	-88.46%	-1233.33%	-100.0%
% of Operating Profit
Other Income/Expense, Net	-$4.055M		$3.671M
YoY Change	-515.47%		183.04%
Pretax Income	-$23.25M	-$18.25M	-$28.76M
YoY Change	33.4%	-69.71%	147.89%
Income Tax	$0.00	$0.00	-$4.282M
% Of Pretax Income
Net Earnings	-$23.25M	-$18.25M	-$24.47M
YoY Change	33.4%	-49.21%	110.97%
Net Earnings / Revenue	-3424.3%	-1087.54%	-1542.09%
Basic Earnings Per Share	-$0.47	-$0.38	-$0.49
Diluted Earnings Per Share	-$417.1K	-$0.38	-$0.49
COMMON SHARES
Basic Shares Outstanding	56.12M shares	55.48M shares	55.40M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2019 Q1	2018 Q4	2018 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$110.6M	$124.6M	$142.0M
YoY Change	-35.88%	-1.42%	61.0%
Cash & Equivalents	$83.97M	$36.94M	$21.93M
Short-Term Investments	$26.60M	$87.70M	$120.1M
Other Short-Term Assets	$700.0K	$2.800M	$1.100M
YoY Change	-53.33%	33.33%	-26.67%
Inventory
Prepaid Expenses
Receivables	$923.0K	$1.431M	$538.0K
Other Receivables	$300.0K	$400.0K	$400.0K
Total Short-Term Assets	$112.5M	$129.2M	$144.0M
YoY Change	-35.79%	-0.11%	58.6%
LONG-TERM ASSETS
Property, Plant & Equipment	$9.667M	$10.15M	$10.42M
YoY Change	-18.28%	-16.73%	-17.44%
Goodwill	$22.47M	$22.47M	$22.47M
YoY Change	-7.77%	-7.77%	-7.77%
Intangibles	$43.84M	$43.84M	$43.84M
YoY Change	-25.25%	-25.25%	-55.92%
Long-Term Investments	$17.68M	$22.22M	$24.67M
YoY Change
Other Assets		$0.00	$0.00
YoY Change		-100.0%	-100.0%
Total Long-Term Assets	$96.73M	$98.68M	$101.4M
YoY Change	1.99%	-8.46%	-31.97%
TOTAL ASSETS
Total Short-Term Assets	$112.5M	$129.2M	$144.0M
Total Long-Term Assets	$96.73M	$98.68M	$101.4M
Total Assets	$209.2M	$227.9M	$245.4M
YoY Change	-22.52%	-3.9%	2.32%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.300M	$3.200M	$3.100M
YoY Change	155.56%	60.0%	34.78%
Accrued Expenses	$6.100M	$7.600M	$6.200M
YoY Change	-4.69%	-11.63%	51.22%
Deferred Revenue		$0.00	$649.0K
YoY Change		-100.0%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$8.823M	$11.24M	$12.67M
YoY Change	-15.13%	-23.16%	53.83%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change		-100.0%	-100.0%
Other Long-Term Liabilities	$6.500M	$3.800M	$4.800M
YoY Change	-36.89%	-65.77%	-56.36%
Total Long-Term Liabilities	$6.500M	$3.800M	$4.800M
YoY Change	-36.89%	-83.55%	-79.13%
TOTAL LIABILITIES
Total Short-Term Liabilities	$8.823M	$11.24M	$12.67M
Total Long-Term Liabilities	$6.500M	$3.800M	$4.800M
Total Liabilities	$28.01M	$27.67M	$30.15M
YoY Change	-25.53%	-49.4%	-58.39%
SHAREHOLDERS EQUITY
Retained Earnings	-$831.2M	-$805.2M	-$784.3M
YoY Change	9.68%	9.1%	12.11%
Common Stock	$882.1M	$879.4M	$878.8M
YoY Change	0.67%	0.38%	0.31%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$181.2M	$200.2M	$215.3M
YoY Change
Total Liabilities & Shareholders Equity	$209.2M	$227.9M	$245.4M
YoY Change	-22.52%	-3.9%	2.32%

Cashflow Statement

Concept	2019 Q1	2018 Q4	2018 Q3
OPERATING ACTIVITIES
Net Income	-$23.25M	-$18.25M	-$24.47M
YoY Change	33.4%	-49.21%	110.97%
Depreciation, Depletion And Amortization	$509.0K	$500.0K	$497.0K
YoY Change	-15.45%	-19.35%	-16.19%
Cash From Operating Activities	-$16.58M	-$17.08M	-$13.20M
YoY Change	-16.96%	65.18%	-15.79%
INVESTING ACTIVITIES
Capital Expenditures	$31.00K	-$230.0K	$237.0K
YoY Change	-87.5%	27.78%	-55.95%
Acquisitions
YoY Change
Other Investing Activities	$61.06M	$45.01M	$12.01M
YoY Change	-180.96%	4901.11%	105.65%
Cash From Investing Activities	$61.03M	$44.78M	$24.38M
YoY Change	-180.66%	6207.04%	359.53%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$2.248M		$0.00
YoY Change	-96.61%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$2.536M	110.0K	$435.0K
YoY Change	-95.34%	-99.78%	613.11%
NET CHANGE
Cash From Operating Activities	-$16.58M	-17.08M	-$13.20M
Cash From Investing Activities	$61.03M	44.78M	$24.38M
Cash From Financing Activities	$2.536M	110.0K	$435.0K
Net Change In Cash	$47.03M	27.81M	$11.74M
YoY Change	-212.42%	-29.18%	-230.63%
FREE CASH FLOW
Cash From Operating Activities	-$16.58M	-$17.08M	-$13.20M
Capital Expenditures	$31.00K	-$230.0K	$237.0K
Free Cash Flow	-$16.61M	-$16.85M	-$13.44M
YoY Change	-17.83%	65.85%	-17.12%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2018	abus	Cumulative Contributionfor Product CumulativeContributionforProduct	2714000	USD
CY2017Q4	abus	Deferred Tax Asset Book Amortization In Excess Of Tax DeferredTaxAssetBookAmortizationInExcessOfTax	650000	USD
CY2018Q4	abus	Deferred Tax Asset Book Amortization In Excess Of Tax DeferredTaxAssetBookAmortizationInExcessOfTax	608000	USD
CY2017Q4	abus	Deferred Tax Asset Revenue Recognized For Tax Purposes In Excess Of Revenue Recognized For Accounting Purposes DeferredTaxAssetRevenueRecognizedForTaxPurposesInExcessOfRevenueRecognizedForAccountingPurposes	1162000	USD
CY2018Q4	abus	Deferred Tax Asset Revenue Recognized For Tax Purposes In Excess Of Revenue Recognized For Accounting Purposes DeferredTaxAssetRevenueRecognizedForTaxPurposesInExcessOfRevenueRecognizedForAccountingPurposes	0	USD
CY2017Q4	abus	Accrued Payroll Current AccruedPayrollCurrent	2893000	USD
CY2018Q4	abus	Accrued Payroll Current AccruedPayrollCurrent	2341000	USD
CY2017Q4	abus	Accrued Researchand Development Current AccruedResearchandDevelopmentCurrent	4937000	USD
CY2018Q4	abus	Accrued Researchand Development Current AccruedResearchandDevelopmentCurrent	2716000	USD
CY2017	abus	Adjustmentsto Additional Paidin Capital Certain Fair Value Adjustmentsto Liability Stock Option Awards AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards	-540000	USD
CY2018	abus	Adjustmentsto Additional Paidin Capital Certain Fair Value Adjustmentsto Liability Stock Option Awards AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards	472000	USD
CY2015Q1	abus	Business Acquisition Equity Interest Issued Or Issuable Value Assigned Attributed As Post Combination Service And Not Included As Part Of Total Purchase Price BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssignedAttributedAsPostCombinationServiceAndNotIncludedAsPartOfTotalPurchasePrice	56934000	USD
CY2017Q1	abus	Classof Warrantor Right Expired ClassofWarrantorRightExpired	22000	shares
CY2018	abus	Cumulative Contributionfor Product CumulativeContributionforProduct	3702000	CAD
CY2017Q4	abus	Deferred Tax Asset Tax Value In Excess Of Accounting Value In Lease Inducements DeferredTaxAssetTaxValueInExcessOfAccountingValueInLeaseInducements	173000	USD
CY2018Q4	abus	Deferred Tax Asset Tax Value In Excess Of Accounting Value In Lease Inducements DeferredTaxAssetTaxValueInExcessOfAccountingValueInLeaseInducements	147000	USD
CY2017Q4	abus	Deferred Tax Asset Upfront License Fees DeferredTaxAssetUpfrontLicenseFees	311000	USD
CY2018Q4	abus	Deferred Tax Asset Upfront License Fees DeferredTaxAssetUpfrontLicenseFees	283000	USD
CY2017Q4	abus	Employee Stock Options Liability Classified Outstanding EmployeeStockOptionsLiabilityClassifiedOutstanding	1239000	USD
CY2018Q4	abus	Employee Stock Options Liability Classified Outstanding EmployeeStockOptionsLiabilityClassifiedOutstanding	479000	USD
CY2017	abus	Fair Value Of Warrants Exercised In The Period FairValueOfWarrantsExercisedInThePeriod	129000	USD
CY2018	abus	Fair Value Of Warrants Exercised In The Period FairValueOfWarrantsExercisedInThePeriod	0	USD
CY2017	abus	Fair Value Warrants Foreign Exchange Gain Loss FairValueWarrantsForeignExchangeGainLoss	0	USD
CY2018	abus	Fair Value Warrants Foreign Exchange Gain Loss FairValueWarrantsForeignExchangeGainLoss	0	USD
CY2017	abus	Increase Decrease In Fair Value Of Contingent Consideration Liability IncreaseDecreaseInFairValueOfContingentConsiderationLiability	1359000	USD
CY2018	abus	Increase Decrease In Fair Value Of Contingent Consideration Liability IncreaseDecreaseInFairValueOfContingentConsiderationLiability	-7298000	USD
CY2017	abus	Increase Decrease In Value Of Warrants IncreaseDecreaseInValueOfWarrants	22000	USD
CY2018	abus	Increase Decrease In Value Of Warrants IncreaseDecreaseInValueOfWarrants	0	USD
	abus	Maximum Contribution For Product MaximumContributionForProduct	7179000	USD
	abus	Maximum Contribution For Product MaximumContributionForProduct	9330000	CAD
CY2017Q4	abus	Net Liquidity NetLiquidity	115706000	USD
CY2018Q4	abus	Net Liquidity NetLiquidity	115188000	USD
CY2006Q2	abus	Number Of Chemotherapy Products With Worldwide Licenses NumberOfChemotherapyProductsWithWorldwideLicenses	3	chemotherapy_products
CY2013Q4	abus	Number Of Executive Officers Granted Options With New Appointments NumberOfExecutiveOfficersGrantedOptionsWithNewAppointments	2	executive_officers
CY2018Q4	abus	Numberof Leases NumberofLeases	3	lease
	abus	Percent Of Costs Funded By Tpc PercentOfCostsFundedByTPC	0.27
CY2016Q4	abus	Restricted Investment Term RestrictedInvestmentTerm	P2Y
CY2019Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	56120868	shares
CY2018	dei	Document Type DocumentType	10-K
CY2018	dei	Entity Central Index Key EntityCentralIndexKey	0001447028
CY2018	abus	Royalty Guarantees Commitments Percentage RoyaltyGuaranteesCommitmentsPercentage	0.025
CY2017Q4	abus	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Options Nonvested Weighted Average Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsNonvestedWeightedAverageFairValue	3.23
CY2018Q4	abus	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Options Nonvested Weighted Average Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsNonvestedWeightedAverageFairValue	3.39
CY2018	abus	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Options Vested In Period Weighted Average Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsVestedInPeriodWeightedAverageFairValue	4.36
CY2017	abus	Tax Cutsand Jobs Actof2017 Incomplete Accounting Changein Tax Rate Deferred Tax Asset Provisional Income Tax Expense TaxCutsandJobsActof2017IncompleteAccountingChangeinTaxRateDeferredTaxAssetProvisionalIncomeTaxExpense	3600000	USD
CY2017	abus	Tax Cutsand Jobs Actof2017 Incomplete Accounting Changein Tax Rate Deferred Tax Liability Provisional Income Tax Benefit TaxCutsandJobsActof2017IncompleteAccountingChangeinTaxRateDeferredTaxLiabilityProvisionalIncomeTaxBenefit	8300000	USD
CY2018	abus	Threshold Period To Pay Accounts Payables ThresholdPeriodToPayAccountsPayables	P45D
CY2017	abus	Warrants Exercised WarrantsExercised	179000	shares
CY2018Q4	abus	Wholly Owned Subsidiaries Includedin Financial Statements WhollyOwnedSubsidiariesIncludedinFinancialStatements	2	subsidiary
CY2018	dei	Amendment Flag AmendmentFlag	false
CY2018	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2018	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2018	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2018
CY2018	dei	Document Period End Date DocumentPeriodEndDate	2018-12-31
CY2018	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2018	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2018	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2018Q2	dei	Entity Public Float EntityPublicFloat	269738700	USD
CY2018	dei	Entity Registrant Name EntityRegistrantName	Arbutus Biopharma Corp
CY2018	dei	Entity Shell Company EntityShellCompany	false
CY2018	dei	Entity Small Business EntitySmallBusiness	true
CY2018	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2018	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2018	invest	Investment Interest Rate InvestmentInterestRate	0.0875
CY2017Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	10646000	USD
CY2018Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	9429000	USD
CY2017Q4	us-gaap	Accounts Payable And Accrued Liabilities Current And Noncurrent AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent	10646000	USD
CY2018Q4	us-gaap	Accounts Payable And Accrued Liabilities Current And Noncurrent AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent	9429000	USD
CY2017Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	1987000	USD
CY2018Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	3192000	USD
CY2017Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	402000	USD
CY2018Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	1431000	USD
CY2017Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	402000	USD
CY2018Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1431000	USD
CY2017Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	429000	USD
CY2018Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	871000	USD
CY2017Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	12671000	USD
CY2018Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	6896000	USD
CY2017Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-48185000	USD
CY2018Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-48170000	USD
CY2017Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	42840000	USD
CY2018Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	48084000	USD
CY2017	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	14858000	USD
CY2018	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	6687000	USD
CY2018	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	1131000	USD
CY2017	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	15117000	USD
CY2018	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6007000	USD
CY2017	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12521550	shares
CY2018	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	24717000	shares
CY2017Q4	us-gaap	Assets Assets	237161000	USD
CY2018Q4	us-gaap	Assets Assets	227905000	USD
CY2017Q4	us-gaap	Assets Current AssetsCurrent	129366000	USD
CY2018Q4	us-gaap	Assets Current AssetsCurrent	129229000	USD
CY2017	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	1359000	USD
CY2018	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-7298000	USD
CY2016Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	9065000	USD
CY2017Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	10424000	USD
CY2018Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	3126000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	23413000	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	54292000	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	36942000	USD
CY2017	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	30879000	USD
CY2018	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-17350000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	126352000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	124617000	USD
CY2018Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	0	shares
CY2017Q4	us-gaap	Common Stock No Par Value CommonStockNoParValue
CY2018Q4	us-gaap	Common Stock No Par Value CommonStockNoParValue
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	55060650	shares
CY2018Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	55518800	shares
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	55060650	shares
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	55518800	shares
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	876108000	USD
CY2018Q4	us-gaap	Common Stock Value CommonStockValue	879405000	USD
CY2017	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-84413000	USD
CY2018	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-57045000	USD
CY2017Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	2742000	USD
CY2018Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	0	USD
CY2017Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	2742000	USD
CY2018Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	0	USD
CY2017	us-gaap	Contribution Of Property ContributionOfProperty	0	USD
CY2018	us-gaap	Contribution Of Property ContributionOfProperty	27377000	USD
CY2017	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-24320000	USD
CY2018	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-4282000	USD
CY2017Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	16943000	USD
CY2018Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	12661000	USD
CY2017Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	693000	USD
CY2018Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	645000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Equity Method Investments DeferredTaxAssetsEquityMethodInvestments	0	USD
CY2018Q4	us-gaap	Deferred Tax Assets Equity Method Investments DeferredTaxAssetsEquityMethodInvestments	37000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	53679000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	71024000	USD
CY2017Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	16603000	USD
CY2018Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	15803000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	36652000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	51575000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Subject To Expiration DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration	13723000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Subject To Expiration DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration	11040000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	2017000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	2503000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	3639000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	4265000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	456000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	307000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	70622000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	83685000	USD
CY2017Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	16943000	USD
CY2018Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	12661000	USD
CY2017Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts	16943000	USD
CY2018Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts	12664000	USD
CY2017	us-gaap	Depreciation Depreciation	2027000	USD
CY2018	us-gaap	Depreciation Depreciation	2181000	USD
CY2017	us-gaap	Dividends Preferred Stock Cash DividendsPreferredStockCash	0	USD
CY2018	us-gaap	Dividends Preferred Stock Cash DividendsPreferredStockCash	10091000	USD
CY2017	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.56
CY2018Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.36
CY2018Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.01
CY2018Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.49
CY2018Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.38
CY2018	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.21
CY2017Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.34
CY2017Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.33
CY2017Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.21
CY2017Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.67
CY2017	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.56
CY2017	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.56
CY2018Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.36
CY2018Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.01
CY2018Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.49
CY2018Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.38
CY2018	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.21
CY2017	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	2372000	USD
CY2018	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-1003000	USD
CY2017	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.26
CY2018	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.27
CY2018Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	9126000	USD
CY2018	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P18M
CY2017Q4	us-gaap	Equity Method Investments EquityMethodInvestments	0	USD
CY2018Q4	us-gaap	Equity Method Investments EquityMethodInvestments	22224000	USD
CY2017	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	-22000	USD
CY2018	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	0	USD
CY2017	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	2301000	USD
CY2018	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-1003000	USD
CY2017	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	2374000	USD
CY2018	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-1003000	USD
CY2017	us-gaap	Gain Loss On Investments GainLossOnInvestments	0	USD
CY2018	us-gaap	Gain Loss On Investments GainLossOnInvestments	24884000	USD
CY2017	us-gaap	Gain Loss On Sale Of Equity Investments GainLossOnSaleOfEquityInvestments	0	USD
CY2018	us-gaap	Gain Loss On Sale Of Equity Investments GainLossOnSaleOfEquityInvestments	-5327000	USD
CY2017	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	3000	USD
CY2018	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	26000	USD
CY2017	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	16129000	USD
CY2018	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	16002000	USD
CY2017Q4	us-gaap	Goodwill Goodwill	24364000	USD
CY2018Q4	us-gaap	Goodwill Goodwill	22471000	USD
CY2017	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2018	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2017	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	40798000	USD
CY2018	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	14811000	USD
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-108733000	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-61342000	USD
CY2017	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	0	USD
CY2018	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-5562000	USD
CY2017	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-24320000	USD
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-4282000	USD
CY2018	us-gaap	Income Tax Expense Benefit Continuing Operations Adjustment Of Deferred Tax Asset Liability IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability	-4282000	USD
CY2017	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	6945000	USD
CY2018	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	13062000	USD
CY2017	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	-6633000	USD
CY2018	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	0	USD
CY2017	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	-966000	USD
CY2018	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	-138000	USD
CY2017	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-28270000	USD
CY2018	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-19287000	USD
CY2017	us-gaap	Income Tax Reconciliation Nondeductible Expense Impairment Losses IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses	0	USD
CY2018	us-gaap	Income Tax Reconciliation Nondeductible Expense Impairment Losses IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses	0	USD
CY2017	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	3128000	USD
CY2018	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	1685000	USD
CY2017	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	1476000	USD
CY2018	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	396000	USD
CY2017Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	340000	USD
CY2018Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	389000	USD
CY2017	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	736000	USD
CY2018	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-1266000	USD
CY2017	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	129000	USD
CY2018	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1029000	USD
CY2017	us-gaap	Increase Decrease In Contract With Customer Asset IncreaseDecreaseInContractWithCustomerAsset	0	USD
CY2018	us-gaap	Increase Decrease In Contract With Customer Asset IncreaseDecreaseInContractWithCustomerAsset	-128000	USD
CY2017	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	2727000	USD
CY2018	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-2742000	USD
CY2017	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	-693000	USD
CY2018	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	0	USD
CY2017	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	47000	USD
CY2018	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	49000	USD
CY2017	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	833000	USD
CY2018	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	648000	USD
CY2017	us-gaap	Increase Decrease In Restructuring Reserve IncreaseDecreaseInRestructuringReserve	0	USD
CY2018	us-gaap	Increase Decrease In Restructuring Reserve IncreaseDecreaseInRestructuringReserve	1331000	USD
CY2017Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	58647000	USD
CY2018Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	43836000	USD
CY2017	us-gaap	Interest Expense InterestExpense	261000	USD
CY2018	us-gaap	Interest Expense InterestExpense	226000	USD
CY2017	us-gaap	Investment Income Interest InvestmentIncomeInterest	1538000	USD
CY2018	us-gaap	Investment Income Interest InvestmentIncomeInterest	3047000	USD
CY2017	us-gaap	Investment Tax Credit InvestmentTaxCredit	183000	USD
CY2018	us-gaap	Investment Tax Credit InvestmentTaxCredit	18000	USD
CY2017Q4	us-gaap	Lease Incentive Payable Current LeaseIncentivePayableCurrent	42000	USD
CY2018Q4	us-gaap	Lease Incentive Payable Current LeaseIncentivePayableCurrent	0	USD
CY2017Q4	us-gaap	Liabilities Liabilities	54688000	USD
CY2018Q4	us-gaap	Liabilities Liabilities	27671000	USD
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	237161000	USD
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	227905000	USD
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	14627000	USD
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	11239000	USD
CY2017Q4	us-gaap	Long Term Loans Payable LongTermLoansPayable	12001000	USD
CY2018Q4	us-gaap	Long Term Loans Payable LongTermLoansPayable	0	USD
CY2017	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	49322000	USD
CY2018	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	55646000	USD
CY2017	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	27825000	USD
CY2018	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-4127000	USD
CY2017	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-48640000	USD
CY2018	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-67866000	USD
CY2017Q1	us-gaap	Net Income Loss NetIncomeLoss	-18627000	USD
CY2017Q2	us-gaap	Net Income Loss NetIncomeLoss	-18255000	USD
CY2017Q3	us-gaap	Net Income Loss NetIncomeLoss	-11600000	USD
CY2017Q4	us-gaap	Net Income Loss NetIncomeLoss	-35931000	USD
CY2017	us-gaap	Net Income Loss NetIncomeLoss	-84413000	USD
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	-17429000	USD
CY2018Q2	us-gaap	Net Income Loss NetIncomeLoss	3091000	USD
CY2018Q3	us-gaap	Net Income Loss NetIncomeLoss	-24473000	USD
CY2018Q4	us-gaap	Net Income Loss NetIncomeLoss	-18249000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-57060000	USD
CY2017Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-18627000	USD
CY2017Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-18255000	USD
CY2017Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-11600000	USD
CY2017Q4	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-36842000	USD
CY2017	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-85324000	USD
CY2018Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-19765000	USD
CY2018Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	550000	USD
CY2018Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-27040000	USD
CY2018Q4	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-20896000	USD
CY2018	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-67151000	USD
CY2017	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2197000	USD
CY2018	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	28438000	USD
CY2018	us-gaap	Number Of Reporting Units NumberOfReportingUnits	1	reporting_unit
CY2017	us-gaap	Operating Expenses OperatingExpenses	121630000	USD
CY2018	us-gaap	Operating Expenses OperatingExpenses	95725000	USD
CY2017Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-18299000	USD
CY2017Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-19485000	USD
CY2017Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-12897000	USD
CY2017Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-60249000	USD
CY2017	us-gaap	Operating Income Loss OperatingIncomeLoss	-110930000	USD
CY2018Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-18405000	USD
CY2018Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-22046000	USD
CY2018Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-32426000	USD
CY2018Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-16903000	USD
CY2018	us-gaap	Operating Income Loss OperatingIncomeLoss	-89780000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	6112000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	787000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	766000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	746000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	3813000	USD
CY2017	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	1653000	USD
CY2018	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	1789000	USD
CY2017Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	358000	USD
CY2018Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	309000	USD
CY2017	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	0	USD
CY2018	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	15000	USD
CY2018	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	15000	USD
CY2017	us-gaap	Payments For Proceeds From Investments PaymentsForProceedsFromInvestments	-35086000	USD
CY2018	us-gaap	Payments For Proceeds From Investments PaymentsForProceedsFromInvestments	3014000	USD
CY2018	us-gaap	Payments For Restructuring PaymentsForRestructuring	3466000	USD
CY2017	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	7264000	USD
CY2018	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1138000	USD
CY2017	us-gaap	Preferred Stock Accretion Of Redemption Discount PreferredStockAccretionOfRedemptionDiscount	0	USD
CY2018	us-gaap	Preferred Stock Accretion Of Redemption Discount PreferredStockAccretionOfRedemptionDiscount	0	USD
CY2017	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	911000	USD
CY2018	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	10091000	USD
CY2017Q4	us-gaap	Preferred Stock Including Additional Paid In Capital Net Of Discount PreferredStockIncludingAdditionalPaidInCapitalNetOfDiscount	49780000	USD
CY2018Q4	us-gaap	Preferred Stock Including Additional Paid In Capital Net Of Discount PreferredStockIncludingAdditionalPaidInCapitalNetOfDiscount	126136000	USD
CY2017Q4	us-gaap	Preferred Stock No Par Value PreferredStockNoParValue
CY2018Q4	us-gaap	Preferred Stock No Par Value PreferredStockNoParValue
CY2017Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1164000000	shares
CY2018Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1164000	shares
CY2017Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	500000000	shares
CY2018Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	1164000	shares
CY2017Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	500000000	shares
CY2018Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	1164000	shares
CY2017Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2144000	USD
CY2018Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2792000	USD
CY2017	us-gaap	Proceeds From Income Tax Refunds ProceedsFromIncomeTaxRefunds	108000	USD
CY2018	us-gaap	Proceeds From Income Tax Refunds ProceedsFromIncomeTaxRefunds	0	USD
CY2017	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	48869000	USD
CY2018	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	66265000	USD
CY2017	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	3000	USD
CY2018	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	25000	USD
CY2017	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	100000	USD
CY2018	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1382000	USD
CY2017	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	353000	USD
CY2017	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	353000	USD
CY2018	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
CY2017	us-gaap	Restructuring Charges RestructuringCharges	0	USD
CY2018	us-gaap	Restructuring Charges RestructuringCharges	4797000	USD
CY2017	us-gaap	Restructuring Costs RestructuringCosts	0	USD
CY2018	us-gaap	Restructuring Costs RestructuringCosts	396000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	24854000	USD
CY2018Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	17041000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	12183000	USD
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	10145000	USD
CY2017	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	0	USD
CY2018	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	12001000	USD
CY2017	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	62676000	USD
CY2018	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	57934000	USD
CY2017Q4	us-gaap	Restricted Investments Noncurrent RestrictedInvestmentsNoncurrent	12601000	USD
CY2018Q4	us-gaap	Restricted Investments Noncurrent RestrictedInvestmentsNoncurrent	0	USD
CY2016Q4	us-gaap	Restricted Investments Noncurrent RestrictedInvestmentsNoncurrent	12601000	USD
CY2017Q4	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	0	USD
CY2018Q4	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	1331000	USD
CY2018	us-gaap	Restructuring Reserve Period Increase Decrease RestructuringReservePeriodIncreaseDecrease	1331000	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-738070000	USD
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-805221000	USD
CY2017Q1	us-gaap	Revenues Revenues	235000	USD
CY2017Q2	us-gaap	Revenues Revenues	1039000	USD
CY2017Q3	us-gaap	Revenues Revenues	6892000	USD
CY2017Q4	us-gaap	Revenues Revenues	2534000	USD
CY2017	us-gaap	Revenues Revenues	10700000	USD
CY2018Q1	us-gaap	Revenues Revenues	1436000	USD
CY2018Q2	us-gaap	Revenues Revenues	1244000	USD
CY2018Q3	us-gaap	Revenues Revenues	1587000	USD
CY2018Q4	us-gaap	Revenues Revenues	1678000	USD
CY2018	us-gaap	Revenues Revenues	5945000	USD
CY2017	us-gaap	Share Based Compensation ShareBasedCompensation	15117000	USD
CY2018	us-gaap	Share Based Compensation ShareBasedCompensation	6241000	USD
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized	3158353	shares
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	6848861	shares
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1520131	shares
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	2620542	shares
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2557669	shares
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	4.08
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	5842000	USD
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	1169784	USD
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	6.05
CY2018	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	2.82
CY2017Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	1098000	USD
CY2018Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	469000	USD
CY2017Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	3198196	shares
CY2018Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	3710546	shares
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares	460586	shares
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P8Y
CY2017	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	5657000	USD
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	6913360	USD
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	1584733	shares
CY2018	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2	P6Y9M7D
CY2017Q4	us-gaap	Short Term Investments ShortTermInvestments	72060000	USD
CY2018Q4	us-gaap	Short Term Investments ShortTermInvestments	87675000	USD
CY2017	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	48869000	USD
CY2018	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	66265000	USD
CY2017	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	481000	USD
CY2017	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	213000	USD
CY2018	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1382000	USD
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	203005000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	182473000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	200234000	USD
CY2017Q4	us-gaap	Unbilled Receivables Current UnbilledReceivablesCurrent	128000	USD
CY2018Q4	us-gaap	Unbilled Receivables Current UnbilledReceivablesCurrent	0	USD
CY2016Q4	us-gaap	Warrants Not Settleable In Cash Fair Value Disclosure WarrantsNotSettleableInCashFairValueDisclosure	107000	USD
CY2017Q4	us-gaap	Warrants Not Settleable In Cash Fair Value Disclosure WarrantsNotSettleableInCashFairValueDisclosure	0	USD
CY2018Q4	us-gaap	Warrants Not Settleable In Cash Fair Value Disclosure WarrantsNotSettleableInCashFairValueDisclosure	0	USD
CY2017	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	54723272	shares
CY2018	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	55304083	shares
CY2017	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	54723272	shares
CY2018	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	55304083	shares
CY2018	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nature of business and future operations</font></div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Arbutus Biopharma Corporation (the “Company” or “Arbutus”) is a biopharmaceutical business dedicated to discovering, developing, and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by the hepatitis B virus (“HBV”). To pursue our strategy of developing a curative combination regimen, the Company has assembled a pipeline of multiple drug candidates with differing and complementary mechanisms of action targeting HBV. </font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The success of the Company is dependent on obtaining the necessary regulatory approvals to bring its products to market and achieve profitable operations. The Company's research and development activities and commercialization of its products are dependent on its ability to successfully complete these activities and to obtain adequate financing through a combination of financing activities and operations. It is not possible to predict either the outcome of the Company's existing or future research and development programs or the Company’s ability to continue to fund these programs in the future.</font></div></div>
CY2018	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of estimates</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions about future events that affect the reported amounts of assets, liabilities, revenue, expenses, contingent assets and contingent liabilities as at the end or during the reporting period. Actual results could significantly differ from those estimates. Significant areas requiring the use of management estimates relate valuation of intangible assets and goodwill, recognition of revenue, stock-based compensation, and the amounts recorded as accrued liabilities, contingent consideration, and income tax recovery.</font></div></div>

Files In Submission

Name	View Source	Status
0001447028-19-000006-index-headers.html	Edgar Link	pending
0001447028-19-000006-index.html	Edgar Link	pending
0001447028-19-000006.txt	Edgar Link	pending
0001447028-19-000006-xbrl.zip	Edgar Link	pending
abus-20181231.xml	Edgar Link	completed
abus-20181231.xsd	Edgar Link	pending
abus-20181231_cal.xml	Edgar Link	unprocessable
abus-20181231_def.xml	Edgar Link	unprocessable
abus-20181231_lab.xml	Edgar Link	unprocessable
abus-20181231_pre.xml	Edgar Link	unprocessable
arbutus10k2018.htm	Edgar Link	pending
exhibit1052execagreemtdhast.htm	Edgar Link	pending
exhibit1053execsigningdhast.htm	Edgar Link	pending
exhibit109formofdoindemnit.htm	Edgar Link	pending
exhibit211_listingofsubsid.htm	Edgar Link	pending
exhibit231_kpmg2018.htm	Edgar Link	pending
exhibit311_10-kcertceo2018.htm	Edgar Link	pending
exhibit312_10-kcertcfo2018.htm	Edgar Link	pending
exhibit321_soxcertceo2018.htm	Edgar Link	pending
exhibit322_soxcertcfo2018.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
hastingsdavidarbutuss_image2.jpg	Edgar Link	pending
hbvlifecyclefinalv2.jpg	Edgar Link	pending
hbvpipelinenoexplanatorytext.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ABUS
Arbutus Biopharma Corp Stock $abus

2019 Q1 Form 10-K Financial Statement

#000144702819000006 Filed on March 07, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ABUS Arbutus Biopharma Corp Stock $abus

2019 Q1 Form 10-K Financial Statement

#000144702819000006 Filed on March 07, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ABUS
Arbutus Biopharma Corp Stock $abus